Lung transplantation in pulmonary sarcoidosis

Kim, Jin Sun; Gupta, Rohit

doi:10.1016/j.jaut.2023.103135

Cited by 2 publications

(1 citation statement)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to International Society for Heart and Lung Transplantation (ISHLT) registry data, sarcoidosis accounts for 2.4% of all lung transplantations, and has a median survival of 6.1 years following transplantation [ 115 , 116 ]. There are no guidelines specifically tailored to sarcoidosis for lung transplantation; they currently follow those for ILD [ 117 , 118 ]. Following the implementation of the lung allocation score (LAS) in 2005, a greater percentage of sarcoidosis patients received lung allografts, leading to reduced waitlist mortality [ 119 ].…”

Section: Managementmentioning

confidence: 99%

Clinical Manifestations and Management of Fibrotic Pulmonary Sarcoidosis

Kim,

Gupta

2023

JCM

Self Cite

View full text Add to dashboard Cite

Fibrotic pulmonary sarcoidosis represents a distinct and relatively uncommon manifestation within the spectrum of sarcoidosis and has substantial morbidity and mortality. Due to the scarcity of research focused on this specific disease subtype, our current understanding of pathogenesis and optimal management remains constrained. This knowledge gap underscores the need for further investigation into areas such as targeted therapies, lung transplantation, and quality of life of patients with fibrotic pulmonary sarcoidosis. The primary aim of this review is to discuss recent developments within the realm of fibrotic pulmonary sarcoidosis to foster a more comprehensive understanding of the underlying mechanisms, prognosis, and potential treatment modalities.

show abstract

Section: Managementmentioning

confidence: 99%

Clinical Manifestations and Management of Fibrotic Pulmonary Sarcoidosis

Kim,

Gupta

2023

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

High-Risk Sarcoidosis: A Focus on Pulmonary, Cardiac, Hepatic and Renal Advanced Diseases, as Well as on Calcium Metabolism Abnormalities

Israël-Biet,

Bernardinello,

Pastré

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Although sarcoidosis is generally regarded as a benign condition, approximately 20–30% of patients will develop a chronic and progressive disease. Advanced pulmonary fibrotic sarcoidosis and cardiac involvement are the main contributors to sarcoidosis morbidity and mortality, with failure of the liver and/or kidneys representing additional life-threatening situations. In this review, we discuss diagnosis and treatment of each of these complications and highlight how the integration of clinical, pathological and radiological features may help predict the development of such high-risk situations in sarcoid patients.

show abstract

Lung transplantation in pulmonary sarcoidosis

Cited by 2 publications

References 90 publications

Clinical Manifestations and Management of Fibrotic Pulmonary Sarcoidosis

Clinical Manifestations and Management of Fibrotic Pulmonary Sarcoidosis

High-Risk Sarcoidosis: A Focus on Pulmonary, Cardiac, Hepatic and Renal Advanced Diseases, as Well as on Calcium Metabolism Abnormalities

Contact Info

Product

Resources

About